NTRA

Natera Inc. Analysis: Natera Inc. (NTRA) has received a high rating of 88% from Validea's Quantitative Momentum Investor model, indicating strong interest based on its fundamentals and valuation in the Biotechnology & Drugs industry.

Wesley Gray's Expertise: Wesley Gray, founder of Alpha Architect and author of notable investment strategy books, is recognized for his expertise in quantitative investing strategies, which inform the analysis of stocks like NTRA.

GeneDx Growth Potential: GeneDx has seen a 1,000% increase in shares over the past year, with expectations for continued growth due to its efficient and accurate genetic testing services, potentially tapping into a market worth over $40 billion.

Other Companies Mentioned: Natera is also poised for significant growth with its cancer monitoring test, Signatera, while Glaukos' new iDose product could revolutionize treatment for eye pressure issues, despite recent stock fluctuations.

DEFINE-HT Study Announcement: Natera, Inc. will present results from the DEFINE-HT study at the ISHLT 45th Annual Meeting, evaluating the relationship between donor-derived cell-free DNA (dd-cfDNA) levels and clinical outcomes in heart transplant recipients using the Prospera™ Heart test.

Potential Impact on Clinical Practice: The study aims to determine if dd-cfDNA can predict adverse outcomes better than traditional biopsy methods, potentially leading to more personalized management of heart transplant patients.

Insider Trading Activity: Jonathan Sheena, a director at $NTRA, sold 181 shares for approximately $26,431, marking a total of 200 insider sales without any purchases in the past six months.

Analyst Ratings and Institutional Moves: Six firms have issued buy ratings for $NTRA stock recently, with a median price target of $160. Additionally, 294 institutional investors increased their holdings while 277 decreased them in the last quarter.

Insider Trading Activity: Steven Leonard Chapman, CEO of $NTRA, sold 6,702 shares for approximately $978,677, representing about 3.2% of his holdings, while insiders have made 203 sales and no purchases in the past six months.

Analyst Ratings and Institutional Activity: Six firms have issued buy ratings for $NTRA stock, with a median price target of $160. Additionally, 294 institutional investors increased their positions, while 277 decreased them in the last quarter.

Insider Trading Activity: Matthew Rabinowitz, Executive Chairman of $NTRA, sold 4,798 shares for approximately $703,296, marking a total of 195 insider sales without any purchases in the past six months.

Analyst Ratings and Institutional Activity: Recent reports show that 5 firms have issued buy ratings for $NTRA, with a median price target of $160. Additionally, 294 institutional investors increased their holdings while 277 decreased them in the last quarter.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Top Upgrades and Downgrades: Notable upgrades include Microsoft, Intel, and Molson Coors, while downgrades were issued for UiPath, Moelis, and Dentsply Sirona due to various market pressures and outlooks.

New Initiations: Truist initiated coverage on UPS and FedEx with Buy ratings, highlighting their strategic growth opportunities, while Canaccord and Citi also initiated coverage on Planet Fitness and Moderna respectively, reflecting positive investment sentiments in these companies.

HEROES Clinical Trial Launch: Natera has initiated the HEROES clinical trial, focusing on de-escalating therapy for approximately 170 patients with metastatic HER2+ breast cancer across 35 sites in France, utilizing their Signatera™ test to monitor treatment response.

Potential Impact on Treatment Protocols: The trial aims to assess the feasibility of safely discontinuing anti-HER2 therapies in patients without detectable disease, which could significantly change treatment approaches and reduce unnecessary healthcare costs.

Insider Trading Activity: Solomon Moshkevich, the president of $NTRA, sold 1,700 shares for approximately $245,008, marking a total of 187 insider sales with no purchases in the last six months.

Institutional and Congressional Trading: In the past quarter, 294 institutional investors increased their holdings in $NTRA while 277 decreased theirs; additionally, members of Congress made one purchase of $NTRA stock without any sales.

Natera's New Patent: Natera, Inc. has received a new patent from the U.S. Patent and Trademark Office for methods related to testing single nucleotide variants in circulating-tumor DNA (ctDNA), enhancing their portfolio of molecular residual disease testing patents.

Company Overview: Natera is a leader in cell-free DNA and genetic testing, focusing on oncology, women's health, and organ health, with over 110 patents in this field and a commitment to integrating personalized genetic testing into standard healthcare practices.

Analyst Rating and Price Target: David Westenberg from Piper Sandler has maintained a Buy rating on Natera (NTRA) with a price target of $205.00, while the current analyst consensus is a Strong Buy with an average price target of $194.93.

Insider Activity and Sentiment: Recent corporate insider activity indicates negative sentiment towards Natera, as there has been an increase in insiders selling shares, including a notable sale by Director Rowan E Chapman.

Natera Inc Stock Performance: Natera Inc (NTRA) shares have entered oversold territory with an RSI of 29.4, indicating potential buying opportunities as the stock trades at $143.11, down from a 52-week high of $183.

Market Comparison: The current RSI for the S&P 500 ETF (SPY) is 39.7, suggesting that while NTRA is experiencing heavy selling, it may be nearing a point of recovery compared to broader market trends.

Natera Inc. Analysis: Natera Inc. (NTRA) has received a high rating of 88% from Validea's Quantitative Momentum Investor model, indicating strong interest based on its fundamentals and valuation in the Biotechnology & Drugs industry.

About Wesley Gray: Wesley Gray, founder of Alpha Architect and expert in quantitative investing, authored notable books on momentum-based stock selection and value investing, contributing to the strategies used by Validea.

Insider Trading Activity: Jonathan Sheena, a director at $NTRA, sold 744 shares for approximately $119,673, representing about 1.7% of his holdings, while insiders have conducted 178 trades in the past six months, all being sales.

Institutional and Congressional Trading: In the last quarter, 294 institutional investors increased their $NTRA holdings, while only one member of Congress traded the stock, making a purchase without any sales.

Analyst Ratings Overview: Natera has received a mix of bullish and bearish ratings from 9 analysts, with recent price targets averaging $192.56, reflecting a 13.44% increase from previous estimates.

Financial Performance Insights: The company shows strong revenue growth of 63.9% but struggles with profitability, indicated by a net margin of -7.18%, while maintaining a conservative debt-to-equity ratio of 0.54.

Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts and exclusive stories to enhance their market strategies.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from accurate stock market intelligence.

Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts and exclusive stories to enhance their market strategies.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from accurate stock market intelligence.

Court Ruling on Patent Case: A federal judge in California overturned a $96 million jury verdict against CareDx, ruling that the patents asserted by Natera were invalid due to insufficient details about the claimed invention.

CareDx's Response: CareDx expressed satisfaction with the court's decision, viewing it as a victory for transplant patients, and stated they would vigorously defend their technology if Natera decides to appeal.

Natera's Signatera Test Coverage: Natera, Inc. announced that its Signatera test has received coverage from CMS for patients with non-small cell lung cancer (NSCLC), expanding Medicare coverage to include surveillance for stage I-III NSCLC, in addition to existing monitoring for immunotherapy.

Significance of the Test: The Signatera test demonstrates high sensitivity and specificity for detecting cancer recurrence earlier than traditional methods, which is crucial given the poor survival rates associated with lung cancer and the limitations of current surveillance tools.